|
GB9004781D0
(en)
*
|
1990-03-02 |
1990-04-25 |
Glaxo Group Ltd |
Device
|
|
GB9012870D0
(en)
*
|
1990-06-08 |
1990-08-01 |
Glaxo Group Ltd |
Device
|
|
GB9016789D0
(en)
*
|
1990-07-31 |
1990-09-12 |
Lilly Industries Ltd |
Medicament administering devices
|
|
US5042472A
(en)
*
|
1990-10-15 |
1991-08-27 |
Merck & Co., Inc. |
Powder inhaler device
|
|
US5337740A
(en)
*
|
1991-08-01 |
1994-08-16 |
New England Pharmaceuticals, Inc. |
Inhalation devices
|
|
DE19647947A1
(en)
*
|
1996-11-20 |
1998-05-28 |
Pfeiffer Erich Gmbh & Co Kg |
Discharge device for media
|
|
SE9900188D0
(en)
*
|
1999-01-22 |
1999-01-22 |
Astra Ab |
Dispensing device
|
|
US6810872B1
(en)
|
1999-12-10 |
2004-11-02 |
Unisia Jecs Corporation |
Inhalant medicator
|
|
US6759398B2
(en)
|
2000-08-05 |
2004-07-06 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative
|
|
WO2002012265A1
(en)
|
2000-08-05 |
2002-02-14 |
Glaxo Group Limited |
6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYL) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT
|
|
GB0103630D0
(en)
|
2001-02-14 |
2001-03-28 |
Glaxo Group Ltd |
Chemical compounds
|
|
ES2296923T3
(en)
|
2001-03-22 |
2008-05-01 |
Glaxo Group Limited |
FORMANILID DERIVATIVES AS AGONISTS OF THE BETA2 ADRENORRECEPTOR.
|
|
US7291608B2
(en)
|
2001-04-30 |
2007-11-06 |
Glaxo Group Limited |
Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α
|
|
EP1416990A1
(en)
*
|
2001-08-09 |
2004-05-12 |
Glaxo Group Limited |
Inhalation device with a pharmaceutical composition
|
|
ATE417606T1
(en)
|
2001-09-14 |
2009-01-15 |
Glaxo Group Ltd |
PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES
|
|
US20030235538A1
(en)
|
2002-04-09 |
2003-12-25 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Method for the administration of an anticholinergic by inhalation
|
|
JP2005523920A
(en)
|
2002-04-25 |
2005-08-11 |
グラクソ グループ リミテッド |
Phenetanolamine derivative
|
|
GB0217225D0
(en)
|
2002-07-25 |
2002-09-04 |
Glaxo Group Ltd |
Medicinal compounds
|
|
DK1556342T3
(en)
|
2002-10-28 |
2008-07-21 |
Glaxo Group Ltd |
Phenethanolamine derivative for the treatment of respiratory diseases
|
|
GB0303396D0
(en)
|
2003-02-14 |
2003-03-19 |
Glaxo Group Ltd |
Medicinal compounds
|
|
PE20050250A1
(en)
|
2003-07-17 |
2005-04-08 |
Glaxo Group Ltd |
ANTAGONISTS OF ACETYLCHOLIN MUSCARINAL RECEPTORS
|
|
MXPA06004244A
(en)
|
2003-10-14 |
2006-06-28 |
Glaxo Group Ltd |
Muscarinic acetycholine receptor antagonists.
|
|
JP2007509061A
(en)
|
2003-10-17 |
2007-04-12 |
グラクソ グループ リミテッド |
Muscarinic acetylcholine receptor antagonist
|
|
AR046225A1
(en)
|
2003-11-04 |
2005-11-30 |
Glaxo Group Ltd |
COMPOSITE OF 8-AZONIABICICLO (3.2.1) OCTOBER, PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES MEDIATED BY MUSCARINIC ACETILCOLINE RECEPTORS THAT UNDERSTAND IT AND USE OF THE COMPOUND TO PREPARE SUCH COMPOSITION
|
|
GB0329182D0
(en)
|
2003-12-17 |
2004-01-21 |
Glaxo Group Ltd |
Chemical compounds
|
|
EP1725564A4
(en)
|
2004-03-17 |
2007-09-12 |
Glaxo Group Ltd |
M3 muscarinic acetylcholine receptor antagonists
|
|
AU2005227733A1
(en)
|
2004-04-02 |
2005-10-13 |
Glaxo Group Limited |
Chemical process and new crystalline form
|
|
AR050902A1
(en)
|
2004-04-27 |
2006-12-06 |
Glaxo Group Ltd |
QUINUCLIDINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USOPRATION TO PREPARE SUCH COMPOSITION
|
|
WO2005112644A2
(en)
|
2004-05-13 |
2005-12-01 |
Glaxo Group Limited |
Muscarinic acetylcholine receptor antagonists
|
|
CN101155590A
(en)
|
2005-02-10 |
2008-04-02 |
葛兰素集团有限公司 |
Method for preparing lactose using a pre-sorting technique and pharmaceutical formulations formed thereby
|
|
TWI389690B
(en)
|
2005-03-25 |
2013-03-21 |
Glaxo Group Ltd |
Novel compounds
|
|
PE20100741A1
(en)
|
2005-03-25 |
2010-11-25 |
Glaxo Group Ltd |
COMPOUNDS DERIVED FROM 3,4-DIHYDROPYRIMIDE [4,5-d] PYRIMIDIN-2 (1H) -ONE AS KINASE INHIBITORS p38
|
|
WO2007022351A2
(en)
|
2005-08-18 |
2007-02-22 |
Glaxo Group Limited |
Muscarinic acetylcholine receptor antagonists
|
|
PE20081889A1
(en)
|
2007-03-23 |
2009-03-05 |
Smithkline Beecham Corp |
INDOL CARBOXAMIDES AS INHIBITORS OF IKK2
|
|
GB2463451A
(en)
|
2008-09-08 |
2010-03-17 |
Cambridge Lab |
3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
|
|
SI2400950T1
(en)
|
2009-02-26 |
2019-09-30 |
Glaxo Group Limited |
Pharmaceutical formulations comprising 4-((1 r)-2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol
|
|
MX2011013679A
(en)
|
2009-06-16 |
2012-01-20 |
Schering Corp |
NOVEL [3,2-c] HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS, COMPOSITIONS AND USES THEREOF.
|
|
GB0921075D0
(en)
|
2009-12-01 |
2010-01-13 |
Glaxo Group Ltd |
Novel combination of the therapeutic agents
|
|
EP2954888A1
(en)
|
2010-08-31 |
2015-12-16 |
GlaxoSmithKline Intellectual Property Development Limited |
Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
|
|
EP2611422B1
(en)
|
2010-08-31 |
2018-10-31 |
GlaxoSmithKline Intellectual Property Development Limited |
Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
|
|
WO2012064286A1
(en)
|
2010-11-11 |
2012-05-18 |
Agency For Science, Technology And Research |
Targeting metabolic enzymes in human cancer
|
|
GB201116641D0
(en)
|
2011-09-27 |
2011-11-09 |
Glaxo Group Ltd |
Novel compounds
|
|
CN104379559B
(en)
|
2012-04-27 |
2016-11-09 |
葛兰素集团有限公司 |
compound
|
|
GB201207406D0
(en)
|
2012-04-27 |
2012-06-13 |
Glaxo Group Ltd |
Novel compounds
|
|
BR112015012312A2
(en)
|
2012-11-28 |
2017-07-11 |
Intercept Pharmaceuticals Inc |
method of treatment, risk reduction, prevention or alleviation of a condition or lung disease in a subject; method of reducing or suppressing lung inflammation in a subject; and method of promoting pulmonary repair in a subject
|
|
RU2017134274A
(en)
|
2015-03-11 |
2019-04-03 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
BINDING TSLP PROTEINS
|
|
HRP20240666T1
(en)
|
2015-06-15 |
2024-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Nrf2 regulators
|
|
RU2018101080A
(en)
|
2015-06-15 |
2019-07-15 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
REGULATORS NRF2
|
|
CA2988373A1
(en)
|
2015-06-15 |
2016-12-22 |
Glaxosmithkline Intellectual Property Development Limited |
Nrf2 regulators
|
|
TW201722965A
(en)
|
2015-08-16 |
2017-07-01 |
葛蘭素史密斯克藍智慧財產發展有限公司 |
Compounds for use in antibacterial applications
|
|
JP2018529745A
(en)
|
2015-10-06 |
2018-10-11 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Biarylpyrazoles as NRF2 regulators
|
|
WO2017060855A1
(en)
|
2015-10-06 |
2017-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Arylcyclohexyl pyrazoles as nrf2 regulators
|
|
TW201825458A
(en)
|
2016-09-20 |
2018-07-16 |
英商葛蘭素史克智慧財產(第二)有限公司 |
TRPV 4 antagonists
|
|
WO2018055526A1
(en)
|
2016-09-20 |
2018-03-29 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Trpv4 antagonists
|
|
EP3515889A1
(en)
|
2016-09-20 |
2019-07-31 |
GlaxoSmithKline Intellectual Property (No. 2) Limited |
Trpv4 antagonists
|
|
CN108779108A
(en)
|
2016-12-06 |
2018-11-09 |
葛兰素史密斯克莱知识产权发展有限公司 |
3- (2,3- dihydro -1H- indenes -5- bases) propanoic derivatives and their purposes as NRF2 conditioning agents
|
|
WO2018109642A1
(en)
|
2016-12-12 |
2018-06-21 |
Glaxosmithkline Intellectual Property Development Limited |
N-aryl pyrazoles as nrf2 regulators
|
|
US20200031820A1
(en)
|
2016-12-12 |
2020-01-30 |
Glsxosmithkline Intellectual Property Development Limited |
3-carboxylic acid pyrroles as nrf2 regulators
|
|
US20220002272A1
(en)
|
2016-12-14 |
2022-01-06 |
Glaxosmithkline Intellectual Property Development Limited |
Bisaryl lactams as nrf2 activators
|
|
US11078216B2
(en)
|
2016-12-14 |
2021-08-03 |
Glaxosmithkline Intellectual Property Development Limited |
Bisaryl amides as NRF2 activators
|
|
WO2018109643A1
(en)
|
2016-12-14 |
2018-06-21 |
Glaxosmithkline Intellectual Property Development Limited |
Bisaryl heterocycles as nrf2 acti
|
|
JP2020502152A
(en)
|
2016-12-15 |
2020-01-23 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Ether-linked triazoles as NRF2 activators
|
|
AU2017376900A1
(en)
|
2016-12-15 |
2019-05-23 |
Glaxosmithkline Intellectual Property Development Limited |
NRF2 compounds
|
|
SMT202100684T1
(en)
|
2017-04-24 |
2022-01-10 |
Cocrystal Pharma Inc |
Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
|
|
EP3723764A1
(en)
|
2017-12-11 |
2020-10-21 |
GlaxoSmithKline Intellectual Property Development Ltd |
Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
|
|
WO2019116231A1
(en)
|
2017-12-11 |
2019-06-20 |
Glaxosmithkline Intellectual Property Development Limited |
Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
|
|
GB201720989D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
CN111868063B
(en)
|
2018-01-17 |
2023-08-01 |
葛兰素史克知识产权开发有限公司 |
PI4KIII beta inhibitors
|
|
EP3796906A1
(en)
|
2018-05-23 |
2021-03-31 |
GlaxoSmithKline Intellectual Property Management Limited |
Indanes as nrf2 activators
|
|
JP7522722B2
(en)
|
2018-07-27 |
2024-07-25 |
コクリスタル ファーマ,インコーポレイテッド |
Pyrrolo[2,3-B]pyridine derivatives as influenza virus replication inhibitors
|
|
CN113286793B
(en)
|
2018-09-10 |
2024-04-05 |
共结晶制药公司 |
Inhibitors of influenza virus replication of pyrrolopyrazines and pyridotriazines
|
|
TWI829785B
(en)
|
2018-10-17 |
2024-01-21 |
美商共結晶製藥公司 |
Combinations of inhibitors of influenza virus replication
|
|
CN113164612A
(en)
|
2018-11-13 |
2021-07-23 |
共晶制药公司 |
Formulations of influenza therapeutics
|
|
WO2020112716A1
(en)
|
2018-11-26 |
2020-06-04 |
Cocrystal Pharma, Inc. |
Inhibitors of influenza virus replication
|
|
GB201908536D0
(en)
|
2019-06-13 |
2019-07-31 |
Glaxosmithkline Ip Dev Ltd |
Compounds
|
|
US20230151034A1
(en)
|
2020-03-17 |
2023-05-18 |
Cocrystal Pharma, Inc. |
Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication
|
|
US20230159453A1
(en)
|
2020-04-10 |
2023-05-25 |
Cocrystal Pharma, Inc. |
Inhibitors of norovirus and coronavirus replication
|
|
US20230158125A1
(en)
|
2020-04-20 |
2023-05-25 |
Sorrento Therapeutics, Inc. |
Pulmonary Administration of ACE2 Polypeptides
|
|
WO2022175425A1
(en)
|
2021-02-22 |
2022-08-25 |
Glaxosmithkline Intellectual Property Development Limited |
Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
|
|
WO2022179967A1
(en)
|
2021-02-23 |
2022-09-01 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Vadadustat for treating covid-19 in a hospitalized subject
|
|
WO2023014758A1
(en)
|
2021-08-03 |
2023-02-09 |
Cocrystal Pharma, Inc. |
Inhibitors for coronaviruses
|